Emergent Biosolutions ROE 2010-2022 | EBS

Current and historical return on equity (ROE) values for Emergent Biosolutions (EBS) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Emergent Biosolutions ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2022-03-31 $0.16B $1.58B 10.03%
2021-12-31 $0.23B $1.62B 14.88%
2021-09-30 $0.23B $1.52B 15.04%
2021-06-30 $0.30B $1.54B 20.81%
2021-03-31 $0.39B $1.52B 28.63%
2020-12-31 $0.31B $1.45B 24.53%
2020-09-30 $0.17B $1.25B 14.47%
2020-06-30 $0.17B $1.20B 15.46%
2020-03-31 $0.07B $1.08B 6.40%
2019-12-31 $0.05B $1.09B 5.27%
2019-09-30 $0.00B $1.04B 0.40%
2019-06-30 $-0.02B $0.99B -1.82%
2019-03-31 $0.04B $0.99B 4.30%
2018-12-31 $0.06B $1.01B 6.64%
2018-09-30 $0.10B $0.97B 10.82%
2018-06-30 $0.11B $0.94B 13.31%
2018-03-31 $0.07B $0.88B 8.84%
2017-12-31 $0.08B $0.91B 11.83%
2017-09-30 $0.09B $0.66B 13.81%
2017-06-30 $0.07B $0.62B 12.29%
2017-03-31 $0.06B $0.61B 9.39%
2016-12-31 $0.05B $0.60B 8.21%
2016-09-30 $0.05B $0.55B 7.38%
2016-06-30 $0.06B $0.67B 9.67%
2016-03-31 $0.09B $0.67B 14.11%
2015-12-31 $0.06B $0.66B 10.49%
2015-09-30 $0.06B $0.61B 10.45%
2015-06-30 $0.04B $0.56B 8.13%
2015-03-31 $0.04B $0.54B 6.69%
2014-12-31 $0.04B $0.55B 7.29%
2014-09-30 $0.02B $0.51B 4.47%
2014-06-30 $0.01B $0.49B 2.71%
2014-03-31 $0.02B $0.48B 3.83%
2013-12-31 $0.03B $0.49B 6.52%
2013-09-30 $0.03B $0.47B 6.91%
2013-06-30 $0.03B $0.45B 5.70%
2013-03-31 $0.02B $0.44B 5.32%
2012-12-31 $0.02B $0.44B 5.63%
2012-09-30 $0.04B $0.43B 8.81%
2012-06-30 $0.03B $0.42B 7.82%
2012-03-31 $0.04B $0.41B 9.53%
2011-12-31 $0.02B $0.42B 6.23%
2011-09-30 $0.02B $0.39B 5.60%
2011-06-30 $0.03B $0.38B 9.19%
2011-03-31 $0.03B $0.36B 8.79%
2010-12-31 $0.05B $0.37B 17.87%
2010-09-30 $0.03B $0.28B 11.61%
2010-06-30 $0.02B $0.26B 7.26%
2010-03-31 $0.02B $0.25B 9.58%
2009-12-31 $0.03B $0.24B 13.42%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.599B $1.793B
Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside of the U.S. BioThrax is the company's key Biodefense product, used for anthrax disease. The U.S. government is the primary purchaser of the company's Biodefense products. It supplies adjuvanted anthrax vaccine candidate, AV7909, to the U.S. government. It supplies smallpox vaccine ACAM2000, botulism therapeutic BAT, anthrax therapeutics 'raxibacumab & Anthrasil' and 3 other products to governments of different countries. It also retails 3 products Narcan nasal spray, Vaxchora and Vivoti. It provides contract development and manufacturing services to multiple pharma and biotech companies. The company has added key products Narcan nasal spray, ACAM2000, raxibacumab, Vaxchora and Vivoti through several acquisitions.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00